HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

Main Article Content

Mazyar Shadman
Joachim Deeg

Keywords

MDS, Transplantation, Elderly

Abstract

The incidence of myeloid malignancies, including myelodysplastic syndromes (MDS) increases with age. While several therapeutic modalities have been developed, for most of these patients the only treatment with curative potential is allogeneic hematopoietic cell transplantation (HCT). The development of reduced/low intensity transplant conditioning regimens allows to successfully transplant patients in their ‘60s and even ‘70s, although comorbidities may determine who does come to transplantation and who does not. Also, as many as half of the patients will develop graft versus host disease (GVHD), even with HLA matched  donors, requiring therapy for extended periods of time,  and GVHD and treatment  with glucocorticoids is likely to impact the quality  of life. Nevertheless, dependent upon disease stage at HCT, the presence of comorbidities and the regimen used, 30% to 50% of patients  60 years of age or older, may survive long-term cured of their disease. Future studies should focus on the incorporation of non-transplant modalities into the overall transplant approach, the prevention of GVHD, and the utilization of immunotherapy to reduce the incidence of relapse and GVHD and further improve overall transplant success.

Downloads

Download data is not yet available.


Abstract 1423
PDF Downloads 586
HTML Downloads 3056

Similar Articles

1 2 3 4 > >> 

You may also start an advanced similarity search for this article.